Baseline, posttreatment, and follow-up data are presented for each group along with change scores and within-group effect sizes. Intention-to-treat sample: I-BMS n = 92, WLC n = 93.
a Between-group effect size. b Within-group effect size of I-BMS. c Within-group effect size of WLC. For IL-6, a significant betweengroup effect was only attained at posttreatment, but not at the 3-month follow-up. Thus, the within-group effect sizes of IL-6 are not calculated at the comparison between T 0 and T 2 in both groups. [9] ) were recruited. Exclusion criteria included self-reported comorbidity with psychotic conditions such as schizophrenia and previous experience with I-BMS. Of the 533 eligible participants, 200 were randomly selected based on a computergenerated list of random numbers because of resource limitations in intervention. Fifteen participants did not provide written consent, and the remaining 185 participants were randomly assigned to either an immediate I-BMS group (n = 92) or a 6-month WLC condition (n = 93). The I-BMS group consisted of eight 3-hour weekly group sessions with culturally relevant mind-body exercises, mindfulness practices, self-reflection via experimental activities, and group discussion and sharing. All measures, including the plasma IL-6 levels via blood test, were collected at baseline (T 0 ), immediately after the intervention (T 1 ), and 3 months after the intervention (T 2 ). The flowchart of the trial is presented in figure 1 . t tests and χ 2 tests were used to compare the baseline characteristics of participants in the I-BMS versus WLC groups. Intention- 56 to-treat analysis was conducted to evaluate treatment effectiveness. Missing data in the I-BMS group were imputed by last observation score and assuming no improvement. The group mean was used to substitute missing values for participants from the WLC group at T 1 and T 2 . The effects of I-BMS intervention were investigated by ANCOVAs with age, gender, and baseline scores as covariates. Cohen's d s were calculated as effect sizes. Forward linear regression analyses of subsamples were performed to examine the effects of I-BMS on changes of PSQI, CESD (minus the item on sleep quality), and IL-6 at T 1 and T 2 for participants with baseline CESD ≥ 16, indicating significant depressive symptoms [8] . The change of each outcome (T 0 -T 1 ) was entered as the dependent variable, whereas the treatment conditions (I-BMS vs. WLC) were the predicting variables, with adjustment for age, gender, baseline scores, and the other two key outcomes.
In this study, 75.1% were female, with a mean age of 55.28 ± 9.83 years. 58.4% had secondary level education, and 72.4% were married or cohabited. A majority (93.7%) of participants reported insomnia that lasted more than 1 year, with 61.1% reporting more than 3 years. Baseline characteristics, including the scores for key outcomes, were comparable between the two groups (I-BMS vs. WLC) and between dropouts and completers. Table 1 displays the descriptive statistics and the within-and between-group effect sizes of the two groups at the three time points. The remission rate of depression (a reduction in CES-D score to <16 [8] ) was significantly greater in the I-BMS group than in the WLC group at . Within-group effect sizes indicate medium to large decreases in PSQI and CESD in the I-BMS group at both T 1 and T 2 . As for IL-6, a medium withingroup effect size was shown at T 1 in the I-BMS group.
Results of regression at both T 1 (n = 103) and T 2 (n = 83) show that I-BMS intervention (WLC = 1; I-BMS = 2) was independently associated with an improvement of PSQI at T 2 but not at T 1 (T 1 : B = 0.98, p = 0.12; T 2 : B = 1.66, p = 0.02). The effect of I-BMS intervention on CESD was found to be significant at T 1 and T 2 (T 1 : B = 5.499, p < 0.001; T 2 : B = 4.05, p = 0.04), but for IL-6 the adjusted treatment effects were only found at T 1 (T 1 : B = 2.04, p = 0.01; T 2 : B = -0.34, p = 0.11).
The current study is the first attempt to test the effect of I-BMS on inflammatory responses alongside other physical (sleep) and mental (depression) health indicators. Our findings indicate the effectiveness of I-BMS in facilitating sleep and alleviating depression, as well as reducing IL-6 levels (at T 1 only). In line with previous findings, the current results support the interconnectivity between the body and the mind [2, 3] , as well as the efficacy of I-BMS in relieving distress in these two reciprocating faculties of human existence [5] [6] [7] . The lack of effect of IL-6 at T 2 could be due to normal fluctuation and variations of plasma IL-6 concentration of the participants.
The current study has several limitations. First, the lack of an active control group compromised the validation of effectiveness. Waitlist control design is limited in detecting specific therapeutic factors that are distinctive from expectation and placebo effects. Future studies may adopt mind-body education or physical exercise programs as active control for examining the therapeutic effect of I-BMS. Second, due to the lack of a standardized diagnostic interview, caution should be taken when generalizing the current findings to a clinical sample. Moreover, insomnia symptoms were collected mainly via subjective reports. Future studies may supplement subjective reports with objective measures, including actigraphy and polysomnography [10] . Currently, there is not sufficient empirical support for the causal direction of the relationships among sleep, mood, and IL-6 [2, 3] . Further intervention and longitudinal studies are needed to provide information on this mindbody relationship by investigating the mediating pathways in the improvement of these indicators.
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